Insights provided by clinical and preclinical trials demonstrated that muscle-enhancing therapeutics, such as myostatin inhibitors, were able to exert beneficial effects in ALS and SMA models and in SMA patients. The gene discussed is MSTN; the disease is amyotrophic lateral sclerosis.